title: [Tuberculosis: new treatment options and updated recommendations].
authors.affiliation: Zentrum für Pneumologie, Diakoniekrankenhaus Rotenburg, Rotenburg. schaberg@diako-online.de
authors.forename: T
authors.initials: T
authors.lastname: Schaberg
mesh_terms: D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001372:Aza Compounds / Q000009:adverse effects / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D003937:Diagnosis, Differential; D064687:Diarylquinolines; D024841:Fluoroquinolones; D005858:Germany; D006801:Humans; D000077266:Moxifloxacin; D009593:Nitroimidazoles / Q000009:adverse effects / Q000627:therapeutic use; D010080:Oxazoles / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use; D012293:Rifampin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D014376:Tuberculosis / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology
chemical_list: D000995:Antitubercular Agents; D001372:Aza Compounds; D064687:Diarylquinolines; D024841:Fluoroquinolones; D009593:Nitroimidazoles; C516022:OPC-67683; D010080:Oxazoles; D011804:Quinolines; C493870:bedaquiline; D000077266:Moxifloxacin; D012293:Rifampin; C018421:rifapentine